# Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

> **NCT02183467** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1356, low dose
- **DRUG:** BI 1356, high dose
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT02183467
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183467, "Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*